Design, synthesis and biological evaluation of a novel bioactive indane scaffold 2-(diphenylmethylene)c-2,3-dihydro-1H-inden-1-one with potential anticancer activity.

Anticancer Benzophenones Cell cycle analysis In vitro cytotoxicity Indanone

Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
01 Sep 2023
Historique:
received: 08 02 2023
revised: 23 06 2023
accepted: 14 07 2023
pubmed: 18 7 2023
medline: 18 7 2023
entrez: 17 7 2023
Statut: ppublish

Résumé

Over the past decades, designing of privileged structures has emerged as a useful approach to the discovery and optimisation of novel biologically active molecules, and many have been successfully exploited across and within different target families. Examples include indole, quinolone, isoquinoline, benzofuran and chromone, etc. In the current study, we focus on synthesising a novel hybrid scaffold constituting naturally occurring benzophenone (14) and indanone (22) ring systems, leading to a general structure of 2-(diphenylmethylene)-2,3-dihydro-1H-inden-1-one (23). It was hypothesised this new hybrid system would provide enhanced anti-cancer activity owing to the presence of the common features associated with the tubulin binding small molecule indanocine (10) and the estrogen receptor (ER) antagonist tamoxifen (24). Key hybrid molecules were successfully synthesised and characterised, and the in vitro cytotoxicity assays were performed against cancer cell lines: MCF7 (breast) and SKBR3 (breast), DU145 (prostate) and A549 (lung). The methyl-, chloro- and methoxy-, para-substituted benzophenone hybrids displayed the greatest degree of cytotoxicity and the E-configuration derivatives 45, 47 and 49 being significantly most potent. We further verified that the second benzyl moiety of this novel hybrid scaffold is fundamental to enhance the cytotoxicity, especially in the SKBR3 (HER2

Identifiants

pubmed: 37459901
pii: S0928-0987(23)00159-8
doi: 10.1016/j.ejps.2023.106529
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106529

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Tao Zhang (T)

School of Food Science and Environmental Health, Technological University Dublin, Grangegorman, Dublin 7, D07 ADY7, Ireland; The Trinity Centre for Natural Products Research (NatPro), School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, D02 PN40, Ireland; Drug Discovery Group, School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland. Electronic address: tao.zhang@TUDublin.ie.

Vilmar Bandero (V)

Drug Discovery Group, School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland. Electronic address: banderv@tcd.ie.

Claire Corcoran (C)

Drug Discovery Group, School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland. Electronic address: corcorcl@tcd.ie.

Ismael Obaidi (I)

The Trinity Centre for Natural Products Research (NatPro), School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, D02 PN40, Ireland; College of Pharmacy, University of Babylon, Babylon, Iraq. Electronic address: obaidii@tcd.ie.

Manuel Ruether (M)

School of Chemistry, Trinity College Dublin, Dublin 2, Ireland. Electronic address: ruetherm@tcd.ie.

John O'Brien (J)

School of Chemistry, Trinity College Dublin, Dublin 2, Ireland. Electronic address: jeobrien@tcd.ie.

Lorraine O'Driscoll (L)

Drug Discovery Group, School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland. Electronic address: lodrisc@tcd.ie.

Neil Frankish (N)

Drug Discovery Group, School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland. Electronic address: nfrnkish@tcd.ie.

Helen Sheridan (H)

The Trinity Centre for Natural Products Research (NatPro), School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, D02 PN40, Ireland; Drug Discovery Group, School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, Ireland. Electronic address: hsheridn@tcd.ie.

Classifications MeSH